Positive News SentimentPositive NewsNASDAQ:PRLD Prelude Therapeutics (PRLD) Stock Forecast, Price & News $2.90 +0.16 (+5.84%) (As of 01:50 PM ET) Add Compare Share Share Today's Range$2.74▼$2.9250-Day Range$2.74▼$4.7952-Week Range$2.65▼$8.66Volume397,035 shsAverage Volume100,396 shsMarket Capitalization$158.95 millionP/E RatioN/ADividend YieldN/APrice Target$9.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Prelude Therapeutics MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside227.6% Upside$9.50 Price TargetShort InterestBearish6.92% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.36) to ($2.14) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.01 out of 5 starsMedical Sector646th out of 963 stocksPharmaceutical Preparations Industry291st out of 451 stocks 3.0 Analyst's Opinion Consensus RatingPrelude Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 2 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.50, Prelude Therapeutics has a forecasted upside of 227.6% from its current price of $2.90.Amount of Analyst CoveragePrelude Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted6.92% of the float of Prelude Therapeutics has been sold short.Short Interest Ratio / Days to CoverPrelude Therapeutics has a short interest ratio ("days to cover") of 16.6, which indicates bearish sentiment.Change versus previous monthShort interest in Prelude Therapeutics has recently increased by 1.16%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldPrelude Therapeutics does not currently pay a dividend.Dividend GrowthPrelude Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PRLD. Previous Next 3.3 News and Social Media Coverage News SentimentPrelude Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.86 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Prelude Therapeutics this week, compared to 1 article on an average week.Search Interest2 people have searched for PRLD on MarketBeat in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Prelude Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders79.54% of the stock of Prelude Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions70.34% of the stock of Prelude Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Prelude Therapeutics are expected to grow in the coming year, from ($2.36) to ($2.14) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Prelude Therapeutics is -1.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Prelude Therapeutics is -1.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPrelude Therapeutics has a P/B Ratio of 0.71. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Prelude Therapeutics (NASDAQ:PRLD) StockPrelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma. The company is also developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 2 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.Read More PRLD Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PRLD Stock News HeadlinesAugust 29, 2023 | finance.yahoo.comPrelude Therapeutics to Participate in Three Healthcare Investor Conferences in SeptemberAugust 29, 2023 | finance.yahoo.comPrelude Therapeutics to Participate in Three Healthcare Investor Conferences in SeptemberSeptember 27, 2023 | Wall Street Fundamentals (Ad)The "Plug and Play" Model Putting Online Giants to ShameWhile e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."August 17, 2023 | msn.comHC Wainwright & Co. Reiterates Prelude Therapeutics (PRLD) Buy RecommendationAugust 17, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Its Buy Rating for Prelude Therapeutics (PRLD)August 3, 2023 | finance.yahoo.comPrelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate UpdateJuly 10, 2023 | finance.yahoo.comWe Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth CarefullyJune 22, 2023 | marketwatch.com8-K: Prelude Therapeutics IncSeptember 27, 2023 | Wall Street Fundamentals (Ad)The "Plug and Play" Model Putting Online Giants to ShameWhile e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."June 22, 2023 | benzinga.comBoard Member at Prelude Therapeutics Acquires Company Stock Options Worth 47,000 SharesJune 4, 2023 | benzinga.comPrelude Therapeutics Stock (NASDAQ:PRLD), Insider Trading ActivityJune 2, 2023 | msn.comThe Prognosis For Prelude TherapeuticsMay 31, 2023 | finance.yahoo.comPrelude Therapeutics To Participate in Jefferies Healthcare ConferenceMay 28, 2023 | finance.yahoo.comKrishna Vaddi Buys Handful Of Shares In Prelude TherapeuticsMay 28, 2023 | finance.yahoo.comKrishna Vaddi Buys Handful Of Shares In Prelude Therapeutics \May 25, 2023 | benzinga.com5.00M Reasons To Be Bullish On Prelude Therapeutics StockMay 18, 2023 | finanznachrichten.dePrelude Therapeutics, Inc.: Prelude Therapeutics Announces Launch of Proposed Public OfferingMay 18, 2023 | finance.yahoo.comPrelude Therapeutics Announces Pricing of Public OfferingMay 8, 2023 | finanznachrichten.dePrelude Therapeutics, Inc.: Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations UpdateMay 8, 2023 | msn.comPrelude Therapeutics GAAP EPS of -$0.58 beats by $0.10May 8, 2023 | finance.yahoo.comPrelude Therapeutics Announces First Quarter 2023 Financial Results and Operations UpdateApril 28, 2023 | marketwatch.comPrelude Therapeutics to Participate in Three Healthcare Investor Conferences in MayApril 27, 2023 | finance.yahoo.comPrelude Therapeutics to Participate in Three Healthcare Investor Conferences in MayApril 11, 2023 | finance.yahoo.comPrelude Therapeutics to Present at American Association for Cancer Research 2023 ConferenceApril 7, 2023 | finance.yahoo.comPrelude Therapeutics Incorporated (NASDAQ:PRLD) most popular amongst private equity firms who own 33% of the shares, institutions hold 24%March 26, 2023 | finance.yahoo.comThe 7 Worst Stocks to Buy NowMarch 17, 2023 | seekingalpha.comPrelude Therapeutics GAAP EPS of $2.44See More Headlines Receive PRLD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Prelude Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address PRLD Company Calendar Last Earnings8/03/2023Today9/27/2023Next Earnings (Estimated)11/13/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PRLD CUSIPN/A CIK1678660 Webwww.preludetx.com Phone302-467-1280FaxN/AEmployees122Year FoundedN/APrice Target and Rating Average Stock Price Forecast$9.50 High Stock Price Forecast$17.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+227.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-115,440,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-54.93% Return on Assets-49.59% Debt Debt-to-Equity RatioN/A Current Ratio17.13 Quick Ratio17.13 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.09 per share Price / Book0.71Miscellaneous Outstanding Shares54,810,000Free Float11,214,000Market Cap$158.95 million OptionableNot Optionable Beta0.33 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Krishna Vaddi D.V.M. (Age 57)Ph.D., Founder, CEO & Director Comp: $805.91kDr. Edna Huang M.D. (Age 50)Pres & Chief Medical Officer Comp: $563.55kDr. Peggy A. Scherle Ph.D. (Age 62)Chief Scientific Officer Comp: $868.62kMr. Laurent Chardonnet M.B.A. (Age 58)Chief Financial Officer Ms. Aimee Crombie Ph.D.Sr. VP and Head of Strategic Planning & OperationsDr. Madhu Pudipeddi Ph.D.Sr. VP of Technical OperationsLindsey TrickettVP of Investor RelationsMr. Bryant David Lim J.D. (Age 52)Chief Legal Officer & Corp. Sec. Ms. Michele Porreca M.B.A.Chief People OfficerDr. Andrew P. Combs Ph.D. (Age 57)Exec. VP & Head of Chemistry More ExecutivesKey CompetitorsMersana TherapeuticsNASDAQ:MRSNCapricor TherapeuticsNASDAQ:CAPRKaryopharm TherapeuticsNASDAQ:KPTIRani TherapeuticsNASDAQ:RANIESSA PharmaNASDAQ:EPIXView All CompetitorsInsiders & InstitutionsBarclays PLCSold 4,270 shares on 9/21/2023Ownership: 0.011%Boxer Capital LLCBought 1,795,971 shares on 8/15/2023Ownership: 4.552%Woodline Partners LPBought 248,000 shares on 8/15/2023Ownership: 0.452%Goldman Sachs Group Inc.Sold 25,708 shares on 8/15/2023Ownership: 0.043%Citadel Advisors LLCBought 1,200 shares on 8/15/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions PRLD Stock - Frequently Asked Questions Should I buy or sell Prelude Therapeutics stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Prelude Therapeutics in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" PRLD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PRLD, but not buy additional shares or sell existing shares. View PRLD analyst ratings or view top-rated stocks. What is Prelude Therapeutics' stock price forecast for 2023? 4 equities research analysts have issued 12 month price objectives for Prelude Therapeutics' stock. Their PRLD share price forecasts range from $5.00 to $17.00. On average, they expect the company's share price to reach $9.50 in the next twelve months. This suggests a possible upside of 227.6% from the stock's current price. View analysts price targets for PRLD or view top-rated stocks among Wall Street analysts. How have PRLD shares performed in 2023? Prelude Therapeutics' stock was trading at $6.04 on January 1st, 2023. Since then, PRLD stock has decreased by 52.0% and is now trading at $2.90. View the best growth stocks for 2023 here. When is Prelude Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023. View our PRLD earnings forecast. How were Prelude Therapeutics' earnings last quarter? Prelude Therapeutics Incorporated (NASDAQ:PRLD) announced its earnings results on Thursday, August, 3rd. The company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.65) by $0.11. When did Prelude Therapeutics IPO? (PRLD) raised $149 million in an initial public offering (IPO) on Friday, September 25th 2020. The company issued 8,300,000 shares at $17.00-$19.00 per share. Morgan Stanley, Goldman Sachs and BofA Securities acted as the underwriters for the IPO. What is Prelude Therapeutics' stock symbol? Prelude Therapeutics trades on the NASDAQ under the ticker symbol "PRLD." Who are Prelude Therapeutics' major shareholders? Prelude Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Boxer Capital LLC (4.55%), BlackRock Inc. (1.57%), Woodline Partners LP (0.45%), Geode Capital Management LLC (0.44%), State Street Corp (0.34%) and Renaissance Technologies LLC (0.33%). Insiders that own company stock include Andrew Combs, Brian Piper, Christopher Pierce, David J Mauro, David J Mauro, Deborah Morosini, Jane Huang, Krishna Vaddi, Laurent Chardonnet, Orbimed Advisors Llc and Peggy Scherle. View institutional ownership trends. How do I buy shares of Prelude Therapeutics? Shares of PRLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Prelude Therapeutics' stock price today? One share of PRLD stock can currently be purchased for approximately $2.90. How much money does Prelude Therapeutics make? Prelude Therapeutics (NASDAQ:PRLD) has a market capitalization of $158.95 million. The company earns $-115,440,000.00 in net income (profit) each year or ($2.35) on an earnings per share basis. How many employees does Prelude Therapeutics have? The company employs 122 workers across the globe. How can I contact Prelude Therapeutics? The official website for the company is www.preludetx.com. The company can be reached via phone at 302-467-1280 or via email at prelude@argotpartners.com. This page (NASDAQ:PRLD) was last updated on 9/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prelude Therapeutics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.